一次情報の記録

重要試験登録の変更

Editas Medicine Receives HREC Approval for Phase 1/2 Strive Study of EDIT-401 in HeFH

Editas received HREC approval and completed CTN with Australia's TGA to initiate the Phase 1/2 Strive study of EDIT-401 in patients with HeFH. The company remains on track to dose patients in 2026, report initial safety/tolerability data in Q1 2027, and topline safety/efficacy from Part 1 in H2 2027. New preclinical NHP data showed durable ≥90% LDL-C reduction over 10 months.

主要事実

提出
2026年11月9日 12:04
イベント
試験登録の変更
方向
ポジティブ
アセット
EDIT-401
出典
SEC 8-K
信頼度
出典あり
ApoB低下
3か月以上にわたって維持された平均約90パーセント
LDL-C低下
10か月以上にわたって維持された90パーセント以上
Lp(a)低下
3か月以上にわたって維持された平均約90パーセント

出典の抜粋

EX-99.1 2 editasmedicinepressrelease.htm EX-99.1 Document Editas Medicine Announces Third Quarter 2026 Results and Business Updates Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study CAMBRIDGE, Mass., November 9, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focu

SEC 8-K

このアセットの詳細

2026年5月26日
10:09
EDITエディタス

Editas Medicine、EAS CongressでEDIT-401の前臨床データを発表

学会発表SEC 8-K
Editas Medicine Receives HREC Approval for Phase 1/2 Strive Study of EDIT-401 in HeFH | SimianX AI